Dr Luis Paz-Ares speaks to ecancer about the efficacy and safety of setidegrasib in patients with advanced NSCLC with KRAS G12D mutation.

He notes that setidegrasib demonstrated encouraging clinical activity, with meaningful response rates in this study.

The treatment also showed signs of biological activity, including suppression of KRAS signalling and potential immunomodulatory effects.

The safety profile was manageable, with most treatment-related adverse events being low grade. Infusion-related reactions were common but mild, and serious adverse events were infrequent, with no treatment discontinuations or deaths attributed to therapy.

Dr Paz-Ares highlights that these findings support continued clinical development of setidegrasib for KRAS G12D mutated lung cancer.